Claims

1. Use of 15 μg recombinant follicle stimulating hormone (rFSH) in the manufacture of a medicament for the treatment of infertility in a patient of age ≥ 35 years, wherein the rFSH includes α2,6-sialylation and α2,3-sialylation wherein 11 % to 15% of the total sialylation is α2, 6-sialyation, and 85% to 89% of the total sialylation is α 2,3-sialyation.